德国四年间儿童和青少年多动障碍治疗直接费用的变化。
Change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in Germany over a period of four years.
机构信息
Medical Department, Lilly Deutschland GmbH, Bad Homburg, Germany.
出版信息
Child Adolesc Psychiatry Ment Health. 2009 Jan 28;3(1):3. doi: 10.1186/1753-2000-3-3.
BACKGROUND
In many developed countries, the treatment of hyperkinetic disorder (or ADHD) consumes a considerable amount of resources. The primary aim of this study was to determine change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in Germany over time, and compare the cost with the cost of treatment for two physical disorders: epilepsy and asthma.
METHODS
The German Federal Statistical Office provided data on the direct cost of treating hyperkinetic disorder, epilepsy and asthma in Germany for 2002, 2004, and 2006. The direct costs of treatment incurred by hyperkinetic disorder in these years were compared with those incurred by epilepsy and asthma.
RESULTS
The total direct cost of treatment for the hyperkinetic disorder was euro 177 million in 2002, euro 234 million in 2004, and euro 341 million in 2006. The largest proportion of the cost was incurred by the age group < 15 years: euro 158 million in 2002, euro 205 million in 2004, and euro 287 million in 2006. The direct cost of treatment for epilepsy in this age group was a total of euro 157 million in 2002, euro 155 million in 2004, and euro 155 million in 2006. For asthma, the total direct cost of treatment in this age group was euro 266 million in 2002, euro 257 million in 2004, and euro 272 million in 2006.
CONCLUSION
The direct cost of treatment for hyperkinetic disorder in the age group < 15 years increased considerably between 2002 and 2006. Over the same period of time and for the same age group, expenditure for epilepsy and asthma was more or less constant. The increase in expenditure for the treatment of hyperkinetic disorder may be due to increasing demand for diagnostic and therapeutic services and improved availability of such services. The study is limited by the difficulty of obtaining consistent data on the direct cost of treatment for both physical and psychiatric disorders in Germany.
背景
在许多发达国家，治疗多动障碍（或 ADHD）消耗了相当多的资源。本研究的主要目的是确定德国儿童和青少年多动障碍治疗的直接成本随时间的变化，并将该成本与两种身体疾病（癫痫和哮喘）的治疗成本进行比较。
方法
德国联邦统计局提供了德国 2002 年、2004 年和 2006 年治疗多动障碍、癫痫和哮喘的直接成本数据。将这几年多动障碍治疗的直接成本与癫痫和哮喘的治疗成本进行了比较。
结果
2002 年，多动障碍的总治疗直接费用为 1.77 亿欧元，2004 年为 2.34 亿欧元，2006 年为 3.41 亿欧元。成本最大的是<15 岁年龄组：2002 年为 1.58 亿欧元，2004 年为 2.05 亿欧元，2006 年为 2.87 亿欧元。该年龄组癫痫治疗的直接费用总额为 2002 年 1.57 亿欧元，2004 年 1.55 亿欧元，2006 年 1.55 亿欧元。对于哮喘，该年龄组的治疗直接总成本为 2002 年 2.66 亿欧元，2004 年 2.57 亿欧元，2006 年 2.72 亿欧元。
结论
2002 年至 2006 年间，<15 岁年龄组多动障碍治疗的直接费用大幅增加。在同一时期和同一年龄组，癫痫和哮喘的支出或多或少保持不变。多动障碍治疗费用的增加可能是由于对诊断和治疗服务的需求增加以及此类服务的可用性提高所致。本研究受到在德国获取身体和精神障碍治疗直接成本的一致性数据困难的限制。
Zotero 插件